Study | Design; Setting; Country$ | Patients (M/F); age | Intervention; duration# | Activation protocol |
---|---|---|---|---|
Bazargani [33] | RCT; Clinic; SWE | EG1: 19 (11/8); 9.7 EG2: 21 (10/11); 10.2 | EG1: TB RME; NR EG2: Hybr. RME; NR | 2×/day until upper palatal molar cusps touch lower molar buccal cusps |
Canan [31] | RCT; Uni; TUR | EG1: 16 (8/8); 12.6 EG2: 16 (7/9); 12.9 EG3: 15 (7/8); 13.4 | EG1: TB RME; 13.3 days EG2: BB RME; 12.4 days EG3: Hybr. RME; 14.1 days | 2×/day |
Celenk-Koca [30] | RCT; Pract; NLD | EG1: 20 (8/12); 13.8 EG2: 20 (7/13); 13.8 | EG1: TB RME; 19.7 days EG2: BB RME; 19.7 days | 2×/day until upper palatal molar cusps touch lower molar buccal cusps |
Feldmann [37] | RCT; Clinic; SWE | EG1: 25 (12/13); 9.7 EG2: 25 (12/13); 10.0 | EG1: TB RME; NR EG2: Hybr. RME; NR | 2×/day until upper palatal molar cusps touch lower molar buccal cusps |
Gunyuz Toklu [18] | RCT; Uni; TUR | EG1: 13 (5/8); 14.3 EG2: 12 (6/6); 13.8 | EG1: TB RME; 19.2 days EG2: Hybr. RME; 20.2 days | 2×/day until upper palatal molar cusps touch lower molar buccal cusps |
Lagravère 2009 [45]collated† | RCT; Uni; CAN | EG1: 20 (5/15); 14.1 EG2: 21 (8/13); 14.2 CG: 21 (6/15); 12.9 | EG1: TB RME; NR EG2: BB RME; NR CG: observation | 2×/day for DME (or 1×/2 days for the SME) until overcorrection |